Dupilumab in patients with diffuse type 2 CRSwNP had beneficial changes in nasal passage microbiota but did not alter gastrointestinal microbiota.

Chronic rhinosinusitis with nasal polyps increases the likelihood of developing coexisting conditions, such as asthma, underscoring the need for more effective, comprehensive treatments.

A survey of ENT clinicians reveals variability in managing chronic rhinosinusitis with nasal polyps, including steroid ...

A study published in July 2025 issue of Journal of Allergy and Clinical Immunology Global highlighted persistent challenges and fragmented care in managing individuals with severe asthma with an ...

Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – ...

PurposeThis review aims to explore the pathophysiological mechanisms and emerging therapies for type 2 chronic rhinosinusitis with nasal polyps (CRSwNP), dri ...

Background and purpose: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition marked by high recurrence and limited therapeutic efficacy. This study investigates the ...

Patients also used mometasone furoate nasal spray. “Dupilumab outperformed omalizumab on all endpoints in both CRSwNP and asthma, while showing generally similar safety profiles,” De Corso said.

Dupilumab improved nasal polyp outcomes and asthma symptoms more than omalizumab in patients with CRSwNP and asthma, according to the head-to-head EVEREST phase 4 trial.